RQRuijin Qiu

Ruijin Qiu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ruijin Qiu has a total of 64 co-authors. Here are the top co-authors by number of shared publications:

  • Hongcai Shang

    Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China

    12 shared publications
  • Shuling Liu

    Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China

    5 shared publications
  • Zhuo Chen

    Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China

    5 shared publications
  • Changming Zhong

    Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital Beijing China

    4 shared publications
  • Mike Clarke

    Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, United Kingdom

    4 shared publications
  • Min Li

    Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, China

    4 shared publications

Latest Publications

  • Open Access

    Development of the core outcome set of traditional Chinese medicine syndromes for bradyarrhythmia based on mixed methods

    by Zhiyue Guan, Xinyi Zhang, Shuling Liu, Chen Zhao, Liang Li, Ruijin Qiu, Hongcai Shang

    Objective: Develop a core outcome set (COS) of traditional Chinese medicine (TCM) syndromes for bradyarrhythmia to provide a standardized reference for the efficacy evaluation of TCM syndromes in clinical research. Methods: A systematic review and a retrospective study were used to construct the original long list of TCM syndromes for bradyarrhythmia. The original list was refined through steering committee meeting and semi - structured interviews. Questionnaires were developed based on the original list, and two rounds of Delphi surveys were conducted among TCM clinicians and researchers. A COS of TCM syndromes for bradyarrhythmia was developed after a consensus meeting. Results: After data extraction and discussion, the COS of TCM syndromes for bradyarrhythmia was constructed in the form of syndrome elements. 13 syndrome elements and their manifestations were included in the round 1 of the Delphi survey. Fifty - four participants completed the round 1 of the Delphi survey, fifty participants completed the round 2 of the Delphi survey, and twelve participants attended the online consensus meeting. Finally, the COS of TCM syndromes for bradyarrhythmia included seven syndrome elements and their manifestations, including syndrome of heart yang deficiency, syndrome of heart qi deficiency, syndrome of heart blood deficiency, syndrome of heart blood stasis obstruction, syndrome of kidney yang deficiency, syndrome of spleen yang deficiency, and phlegm syndrome. Conclusion: The COS of TCM syndromes for bradyarrhythmia can help researchers select the outcomes reported in clinical trials and improve the consistency of the efficacy evaluation of TCM syndromes in clinical trials.

  • Open Access

    Development of a framework to improve the quality and value of choosing outcomes in cardiovascular disease research (FAVOUR): a study protocol

    by Ruijin Qiu, Shuangqiu Wang, Changhe Yu, Chen Zhao, Zhiyue Guan, Siyi Li, Lulu Shi, Ying-Hui Jin, Min Li, Shuling Liu, et al.

    Background: Selecting appropriate outcomes is crucial for enhancing the comparability and relevance of clinical trials, yet uptake of core outcome sets (COS) remains low. This study aims to develop a framework to improve the quality and value of choosing outcomes in cardiovascular disease research (FAVOUR), so that the uptake of COS may be improved. Methods: The mixed-methods will be used to develop a framework: (1) a systematic review will be conducted to identify current rationales, values and preferences of different stakeholders of outcome selection in clinical trials; (2) semi-structured interviews with patients and healthcare professionals will be used to identify the evidence, values and preferences of different stakeholders in outcome selection and measurement; (3) two rounds of Delphi survey will be conducted to prioritise items for the framework; and (4) a consensus meeting will be carried out to finalise the framework. Ethics and dissemination: This study has been approved by the ethics committee of Dongzhimen Hospital, Beijing University of Chinese Medicine (Approval No.: 2025DZMEC-148-02). The results will be disseminated through peer-reviewed journals and conference presentations. Trial registration number: This research has been registered in the Core Outcome Measures in Effectiveness Trial database ( https://www.comet-initiative.org/Studies/Details/3723 ).

  • Uptake of Core Outcome Sets (COS) in China

    by Ruijin Qiu, Shuling Liu, Wenhui Wang, Zhuo Chen, Mike Clarke, Sarah L. Gorst, Susanna Dodd, Anna Kearney, Xiaodan Fan, Yinghui Jin, et al.


  • Open Access

    Uptake of core outcome sets by clinical trialists in China: a protocol

    by Ruijin Qiu, Xiaodan Fan, Wenhui Wang, Mike Clarke, Zhuo Chen, Shuling Liu, Paula Williamson, Hongcai Shang

    Background The concept of core outcome sets (COS) has been introduced in China for about 10 years. In recent years, some Chinese researchers also committed to developing COS, though the majority of COS are ongoing. However, there were more than 500 published COS for research in the COMET database by 2020. The extent of availability of COS for the top 25 diseases with the highest burden in China is unknown. In addition, the uptake of COS in clinical trials for these diseases is unknown, along with the knowledge, perceptions, and views of the clinical trialist community in China on the use of COS in relation to choosing outcomes for their research. Methods The main burden of disease in China will be identified. Then we will search the COMET database to identify if there are ongoing or completed relevant COS research A COS published since 2012 would be preferred to one published before 2012 for the analysis of COS uptake if one meets the eligibility criteria. We will extract scopes of published eligible COS, including condition, population, interventions, and core outcomes. Then we will search the Chinese Clinical Trial Registry using disease names for each disease that has a published COS. We will assess the overlap in scope between clinical trials and COS. Then we will conduct an online survey and semi-structured interviews to identify the knowledge and perceptions of COS among primary investigators of included clinical trials. Discussion This research will fill in gaps between COS and the burden of disease in China. Understanding clinical trialists’knowledge and perceptions of COS may help dissemination and application of COS in the future. Trial registration This research is registered in Core Outcome Measures in Effectiveness: https://www.comet-initiative.org/Studies/Details/2563.

  • Open Access

    Development of a core outcome set for cardiac rehabilitation in patients with myocardial infarction: a study protocol

    by Zhiyue Guan, Xinyi Zhang, Yinghui Jin, Ruijin Qiu, Hongcai Shang

    Introduction Heterogeneous outcome reporting is common in clinical trials focused on cardiac rehabilitation for myocardial infarction (MI); this practice often results in the exclusion of data from clinical trials in systematic reviews. Developing a core outcome set (COS) may solve this problem. Methods and analysis We will first identify a preliminary list of outcomes through a systematic review. Next, we will conduct semistructured interviews with patients to explore additional potential outcomes deemed important by patients. Then, we will engage various stakeholders such as clinicians, researchers and methodologists in two Delphi survey tends to refine and prioritise the identified outcomes. Subsequently, we will gather insights directly from patients with MI by administering plain language patient surveys; patients will be involved in questionnaire development. Finally, we will hold two face-to-face consensus meetings for patients and other stakeholders to develop the final COS for cardiac rehabilitation in MI. Ethics and dissemination The Ethics Committee of Dongzhimen Hospital, Beijing University of Chinese Medicine approved this study (2022DZMEC-349). The final COS will be published in a peer-reviewed journal and disseminated in conferences. Trial registration We registered this study in the Core Outcome Measures in Effectiveness Trials Initiative (COMET) platform. Registration number: 1725 (http://www.comet-initiative.org/studies/details/1725).


  • Open Access

    Uptake of core outcome sets by clinical trialists in China: a protocol

    by Ruijin Qiu, Xiaodan Fan, Wenhui Wang, Mike Clarke, Zhuo Chen, Shuling Liu, Paula Williamson, Hongcai Shang

    Background The concept of core outcome sets (COS) has been introduced in China for about 10 years. In recent years, some Chinese researchers also committed to developing COS, though the majority of COS are ongoing. However, there were more than 500 published COS for research in the COMET database by 2020. The extent of availability of COS for the top 25 diseases with the highest burden in China is unknown. In addition, the uptake of COS in clinical trials for these diseases is unknown, along with the knowledge, perceptions, and views of the clinical trialist community in China on the use of COS in relation to choosing outcomes for their research. Methods The main burden of disease in China will be identified. Then we will search the COMET database to identify if there are ongoing or completed relevant COS research A COS published since 2012 would be preferred to one published before 2012 for the analysis of COS uptake if one meets the eligibility criteria. We will extract scopes of published eligible COS, including condition, population, interventions, and core outcomes. Then we will search the Chinese Clinical Trial Registry using disease names for each disease that has a published COS. We will assess the overlap in scope between clinical trials and COS. Then we will conduct an online survey and semi-structured interviews to identify the knowledge and perceptions of COS among primary investigators of included clinical trials. Discussion This research will fill in gaps between COS and the burden of disease in China. Understanding clinical trialists’knowledge and perceptions of COS may help dissemination and application of COS in the future. Trial registration This research is registered in Core Outcome Measures in Effectiveness: https://www.comet-initiative.org/Studies/Details/2563.


  • Core outcome sets for myocardial infarction in clinical trials of traditional Chinese medicine and Western medicine

    by Ruijin Qiu, Siqi Wan, Changming Zhong, Songjie Han, Tianmai He, Ya Huang, Xuxu Wei, Meng Li, Zhiyue Guan, Xinyi Zhang, et al.

    Background: Clinical trials of traditional Chinese medicine (TCM) and Western medicine showed there was heterogeneity of outcome reporting in myocardial infarction (MI). Developing a core outcome set (COS) might improve the consistency of outcome reporting in future clinical trials.Methods: A list of outcomes was developed based on a systematic review of randomized controlled trials (RCTs) of MI and semistructured interviews with MI patients. Two rounds of Delphi survey for clinicians, researchers, journal editors, and methodologists were conducted. An online questionnaire sent to nurses. After an online consensus meeting, a COS for MI RCTs was developed.Results: After extracted data from clinical trials and discussed, 216 outcomes were included in round 1 of the Delphi survey. Seventy‐four participants completed round 1 of the Delphi survey. Sixty‐five participants completed round 2 of the Delphi survey. Twenty‐two nurses completed the online questionnaire. Fifteen participants attended the online consensus meeting, and 14 of them voted and determined the final COS. For all types of MI, it was recommended that left ventricular ejection fraction and quality of life be measured and reported. For acute MI, the participants in the consensus meeting recommended the following core outcomes: death from cardio‐cerebrovascular disease, cardiogenic shock, heart failure, troponin I, troponin T, creatine kinase isoenzyme, Killip class, target vessel revascularization, and emergency CABG. For previous MI, recurrent MI, recurrent angina pectoris, and heart failure readmission were recommended.Conclusions: The COS for MI in RCTs provides recommendations for clinical trials that seek to improve outcomes for patients with MI.


  • Open Access

    Uptake of core outcome sets by clinical trialists in China: a protocol

    by Ruijin Qiu, Xiaodan Fan, Wenhui Wang, Mike Clarke, Zhuo Chen, Shuling Liu, Paula Williamson, Hongcai Shang

    Background: The concept of core outcome sets (COS) has been introduced in China for about 10 years. In recent years, some Chinese researchers also committed to developing COS, though the majority of COS are ongoing. However, there were more than 500 published COS for research in the COMET database by 2020. Whether the disease category of ongoing and completed COS include the burden of disease in China is unclear. In addition, whether the published COS are used by clinical trialists is also unclear. In this research, we would like to investigate if COS are applicable to the burden of disease in China, and to ascertain whether completed COS are used by clinical trialists in China. Methods: The main burden of disease in China will be identified. Then we will search the COMET database to identify if there are ongoing or completed relevant COS research since 2012. Only COS for clinical trials or clinical research will be included. We will extract scopes of published eligible COS, including condition, population, interventions, and core outcomes. Then we will search the Chinese Clinical Trial Registry using disease names for each disease that has a published COS. We will assess the overlap in scope between clinical trials and COS. Then we will conduct an online survey and semi-structured interviews to identify the knowledge and perceptions of COS among primary investigators of included clinical trials. Discussion: This research will fill in gaps between COS and the burden of disease in China. Understanding clinical trialists’ knowledge and perceptions of COS may help dissemination and application of COS in the future. Trial registration: This research is registered in Core Outcome Measures in Effectiveness: https://www.comet-initiative.org/Studies/Details/2563.


  • Open Access

    Developing a core outcome set for assessing clinical safety outcomes of cardiovascular diseases in clinical trials of integrated traditional Chinese medicine and Western medicine: study protocol

    by Ruijin Qiu, Changming Zhong, Siqi Wan, Yao Zhang, Xuxu Wei, Min Li, Jiayuan Hu, Shiqi Chen, Chen Zhao, Zhao Chen, et al.

    Background: Integrative medicine is commonly used in China. Researchers prefer to report efficacy outcomes rather than safety outcomes in clinical trials; thus, evidence regarding safety in integrative medicine is unclear. Developing a core outcome set (COS) for safety outcomes is necessary. In this study, a representative example of the methodology for developing COS to assess safety outcomes of cardiovascular diseases in clinical trials investigating integrated medicine will be developed. Methods and analysis: Safety information will be extracted from package inserts and through systematic reviews of treatments for cardiovascular diseases (including angina pectoris, myocardial infarction, heart failure, arrhythmia, and hypertension) to develop an extensive list of safety outcomes, which will then be categorized according to whether subjective or objective outcomes. Questionnaires for clinician-reported safety outcomes and patient-reported safety outcomes will be developed. Two rounds of the Delphi survey will then be conducted for different stakeholders (traditional Chinese medicine clinicians and researchers in cardiovascular diseases, Western medicine clinicians and researchers in cardiovascular diseases, integrated medicine clinicians and researchers of cardiovascular diseases, pharmacologists, methodologists of evidence-based medicine, and patients). After round 2 of the Delphi analysis, a face-to-face consensus meeting will be held to determine the final COS for assessing safety outcomes in cardiovascular diseases. Discussion: A COS for safety outcomes in cardiovascular diseases may improve the consistency of reporting results and will help identify potential bias of selective reporting in the future. Trial registration: This study was registered in the Core Outcome Measures in Effectiveness Trials database as study 1564.


  • Open Access

    Potential Acupoint Prescriptions and Outcome Reporting for Acupuncture in Atopic Eczema: A Scoping Review

    by Zhiwen Zeng, Man Li, Yunjie Zeng, Jialing Zhang, Yingjie Zhao, Yuanxun Lin, Ruijin Qiu, Dong-Shu Zhang, Hong-Cai Shang

    Background. Acupuncture is considered a complementary therapy for atopic eczema. The aim of this scoping review is to identify, examine, and summarize the potential acupoint prescriptions and outcome reporting regarding the clinical trials of acupuncture for eczema. Methods. We searched different databases from inception to September 30, 2020. The data were screened and extracted to identify the potential acupuncture prescription and examine the variation in outcome reporting, outcome measurement instruments (OMIs), and measurement time points in clinical trials of acupuncture. Results. A total of 116 clinical studies were included. The acupoint combination of LI11 and SP10 was used frequently. The core acupoint association networks were acupoints LI11, SP10, ST36, SP6, and LI4. For clinical trials of acupuncture, a total of 6 outcome distinct domains were identified in the 32 outcome measurements. The most frequently reported outcome was the eczema area, which was reported 97 times (83.6, 97/116). Immune system outcomes were assessed in 15 outcome measurements, which totally reported 37 times. Adverse events were reported 51 times. TCM syndrome, which could reflect the characteristics of TCM, was reported 4 times. 29 outcomes (90.6, 29/32) were provided definitions or OMIs. Among these outcomes, the outcome measurement times ranged from 0 to 34. Conclusions. This scoping review provides potential knowledge that should be considered as priority in future research of acupuncture for eczema.